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Background
Poxvirus vector Modified Vaccinia Virus Ankara (MVA)
expressing HIV-1 Env, Gag, Pol and Nef antigens from
clade B (termed MVA-B) is a promising HIV/AIDS vac-
cine candidate, as it was shown in the results obtained
from a phase I clinical trial.
Methods
To try to improve the immunogenicity elicited by MVA-B
we have generated and characterized the innate immune
sensing and the in vivo immunogenicity profile of new
optimizing MVA-B vaccine candidates, which contains
deletions in one, two or three different immunomodula-
tory vaccinia virus (VACV) genes blocking the same sig-
naling pathway, involved in the induction of type I IFN.
Results
The innate immune signals elicited by these MVA-B
deletion mutants in human macrophages showed an up-
regulation of the expression of IFN-b and IFN-a/b-
inducible genes. A DNA prime/MVA boost immuniza-
tion protocol in mice revealed that these MVA-B dele-
tion mutants were able to induce strong and
polyfunctional HIV-1-specific CD4+ and CD8+ T-cell
adaptive and memory immune responses, which were
mostly mediated by CD8+ T cells with an effector phe-
notype. CD4+ T-cell responses were mainly directed
against Env in MVA-B and all the MVA-B deletion
mutants. However and interestingly, while MVA-B
induced preferentially Env- and Gag-specific CD8+
T-cell responses, MVA-B deletion mutants induced
more GPN-specific CD8+ T-cell responses. Moreover,
an enhanced HIV-1-specific lymphoproliferative
response was observed with the MVA-B deletion
mutants. Furthermore, MVA-B and MVA-B deletion
mutants were also able to induce antibodies against Env.
Conclusion
These findings revealed that deletion in MVA-B of
VACV genes that act blocking the same signaling path-
way confers an immunological benefit by inducing innate
immune responses and increasing the magnitude, quality
and durability of the HIV-1-specific T-cell immune
responses. Our observations focused the use of highly
optimizing MVA-based vectors as more potent HIV-1
vaccines.
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